Literature DB >> 6587749

Hemodynamic effects of verapamil in essential hypertension at rest and during exercise.

P Lund-Johansen.   

Abstract

In recent years the calcium antagonist verapamil has been used in the treatment of essential hypertension. Relatively little work has been done to elucidate its long-term haemodynamic effects at rest and during exercise. Ten males with previously untreated essential hypertension in WHO stage I, aged 35-55 years, were studied on an outpatient basis. Oxygen consumption, heart rate, cardiac output ( Cardiogreen ) and intra-arterial brachial pressure were recorded at rest in the supine and sitting position and during steady state work at 50, 100 and 150 W. As expected, the hypertension was associated with an increase in total peripheral resistance. The subjects were treated with verapamil 120-240 mg daily as the sole drug for one year. The haemodynamic study was then repeated. One subject demonstrated a slight increase in blood pressure at rest and during exercise, while there was a blood pressure reduction in the other 9. The nonresponding patient was excluded from the statistical evaluation. The main results were as follows: There was a statistically significant reduction in systolic, diastolic and mean arterial pressure at rest as well as during exercise. The reductions reached about 10% at rest, slightly less during exercise. The blood pressure reduction was associated with a statistically significant reduction in total peripheral resistance at rest only. During exercise, the reduction in resistance was modest (about 5%). The heart rate was practically unchanged during supine rest, but decreased about 8% at rest sitting and during exercise.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6587749     DOI: 10.1111/j.0954-6820.1984.tb08684.x

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  11 in total

1.  The effect of verapamil on cardiovascular and metabolic responses to exercise.

Authors:  H Petri; B G Arends; M A van Baak
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1986

2.  Acute and long-term hemodynamic effects of tiapamil at rest and during exercise in essential hypertension.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

3.  Correction of physiological alterations of hypertension.

Authors:  E D Frohlich
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 4.  Studies on verapamil in the treatment of essential hypertension: a review.

Authors:  K Midtbø; O Hals; O Lauve; J van der Meer; L Storstein
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 5.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

6.  Nicardipine in the treatment of essential hypertension controlled 6-month-study comparing nicardipine with propranolol at rest and during exercise.

Authors:  A Danielsson; P Bjerle; B Ek; L Steen; O Suhr
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  The haemodynamic effects of long term felodipine therapy in previously untreated essential hypertension.

Authors:  S Capewell; C G Wathen; W J Hannan; A L Muir
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

9.  Hemodynamic effects of Ro 23-6152 in patients with essential hypertension.

Authors:  H B Folkers; J C van Zwienen; P Boer; C H Kleinbloesem; G G Geyskes
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 10.  Calcium antagonists and exercise performance.

Authors:  W Kindermann
Journal:  Sports Med       Date:  1987 May-Jun       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.